{"log_id": 6577173198200300189, "direction": 0, "words_result_num": 51, "words_result": [{"probability": {"variance": 0.002483, "average": 0.984775, "min": 0.723258}, "location": {"width": 732, "top": 51, "height": 39, "left": 328}, "words": "药效学:体内体外研究均表明,西妥昔单抗可以抑制表达EGFR的人类肿瘤细胞的增"}, {"probability": {"variance": 0.000136, "average": 0.994554, "min": 0.930487}, "location": {"width": 772, "top": 84, "height": 33, "left": 287}, "words": "殖并诱导其凋亡。在体外,本品能抑制肿瘤细胞分泌的血管生成因子并阻遏内皮细胞的"}, {"probability": {"variance": 5.8e-05, "average": 0.997717, "min": 0.952401}, "location": {"width": 775, "top": 111, "height": 38, "left": 283}, "words": "迁移。在体内,本品可以抑制肿瘤细胞血管生成因子的表达以减少肿瘤血管的生成和转"}, {"probability": {"variance": 0.000637, "average": 0.964427, "min": 0.943397}, "location": {"width": 157, "top": 138, "height": 54, "left": 152}, "words": "药有限"}, {"probability": {"variance": 8.2e-05, "average": 0.99566, "min": 0.949604}, "location": {"width": 732, "top": 171, "height": 36, "left": 324}, "words": "免疫原性:单克隆嵌合抗体进入人体内引发抗原抗体反应,从而产生人抗嵌合抗体"}, {"probability": {"variance": 0.006738, "average": 0.978374, "min": 0.481347}, "location": {"width": 742, "top": 201, "height": 36, "left": 301}, "words": "FACA),但目前有关HACA产生过程的数据有限。在所有已进行的目标适应症的研究中"}, {"probability": {"variance": 0.002878, "average": 0.987161, "min": 0.639033}, "location": {"width": 771, "top": 230, "height": 38, "left": 281}, "words": "37%的患者检测到了HACA的滴度,其发生率为0%-9.6%。到目前为止,尚无HACA中和"}, {"probability": {"variance": 0, "average": 0.873682, "min": 0.873682}, "location": {"width": 160, "top": 235, "height": 137, "left": 95}, "words": "当"}, {"probability": {"variance": 0.007172, "average": 0.975304, "min": 0.545745}, "location": {"width": 698, "top": 261, "height": 35, "left": 281}, "words": "西妥昔单抗的结论性数据。HACA的产生与超敏反应或其它不良反应的发生无关"}, {"probability": {"variance": 0, "average": 0.999663, "min": 0.999375}, "location": {"width": 46, "top": 295, "height": 23, "left": 320}, "words": "毒理"}, {"probability": {"variance": 0.000207, "average": 0.995913, "min": 0.911699}, "location": {"width": 732, "top": 321, "height": 37, "left": 318}, "words": "在使用人类治疗剂量的等效剂量作为起始剂量进行的恒河猴毒理试验中(长期反复"}, {"probability": {"variance": 0.001047, "average": 0.992733, "min": 0.795731}, "location": {"width": 772, "top": 350, "height": 38, "left": 277}, "words": "给药毒理试验和胚胎胎儿发育毒理试验中),主要观察到剂量依赖性的皮肤毒性。当猴体"}, {"probability": {"variance": 1e-06, "average": 0.998981, "min": 0.996039}, "location": {"width": 770, "top": 380, "height": 37, "left": 276}, "words": "浓度达到人临床标准治疗时体内血药浓度的17倍时,本品能引起猴的严重皮肤毒性及"}, {"probability": {"variance": 5e-06, "average": 0.998318, "min": 0.994583}, "location": {"width": 123, "top": 413, "height": 24, "left": 276}, "words": "致命的综合症"}, {"probability": {"variance": 5.3e-05, "average": 0.996752, "min": 0.956488}, "location": {"width": 725, "top": 439, "height": 35, "left": 317}, "words": "在恒河猴中进行的胚胎胎儿发育毒理研究中未发现本品具有致畸作用。然而,随着剂"}, {"probability": {"variance": 0.000203, "average": 0.989827, "min": 0.956954}, "location": {"width": 233, "top": 470, "height": 26, "left": 277}, "words": "量的增加,流产率出现升高"}, {"probability": {"variance": 2.2e-05, "average": 0.997744, "min": 0.981044}, "location": {"width": 720, "top": 498, "height": 33, "left": 322}, "words": "在其他非临床研究,包括遗传毒理研究和正常给药途径之外的意外给药途径在内的局"}, {"probability": {"variance": 4.4e-05, "average": 0.996339, "min": 0.970344}, "location": {"width": 412, "top": 528, "height": 26, "left": 276}, "words": "部耐受性试验中,未发现本品对人具有特殊毒性"}, {"probability": {"variance": 0.004546, "average": 0.984644, "min": 0.597481}, "location": {"width": 691, "top": 556, "height": 33, "left": 313}, "words": "尚未进行正式的西妥昔单抗致癌性、以及对雄性和雌性动物生殖能力的影响试验"}, {"probability": {"variance": 0.000211, "average": 0.993577, "min": 0.93156}, "location": {"width": 464, "top": 584, "height": 32, "left": 314}, "words": "尚未进行西妥昔单抗与伊立替康联合用药的毒性研究"}, {"probability": {"variance": 0.00028, "average": 0.992261, "min": 0.914832}, "location": {"width": 724, "top": 614, "height": 34, "left": 311}, "words": "到目前为止,尚无抗EGFR抗体对伤口愈合的非临床数据。然而,非临床伤口愈合"}, {"probability": {"variance": 0.000326, "average": 0.991996, "min": 0.911042}, "location": {"width": 499, "top": 643, "height": 31, "left": 270}, "words": "模型显示EGFR选择性酪氨酸激酶抑制剂能延迟伤口愈合"}, {"probability": {"variance": 1.3e-05, "average": 0.996619, "min": 0.98947}, "location": {"width": 110, "top": 681, "height": 24, "left": 279}, "words": "【临床试验】"}, {"probability": {"variance": 0.016003, "average": 0.950409, "min": 0.472183}, "location": {"width": 722, "top": 710, "height": 32, "left": 310}, "words": "通过免疫组化方法检测肿瘤组织的EGFR表达( bgffr-phairm.Dx2如果检测到一个"}, {"probability": {"variance": 0.006043, "average": 0.974732, "min": 0.538426}, "location": {"width": 770, "top": 735, "height": 38, "left": 265}, "words": "染色细胞,即认定该肿瘤为EGFR阳性。已有的临床试验中药80%的转移性结直肠癌患"}, {"probability": {"variance": 0.011495, "average": 0.957283, "min": 0.576902}, "location": {"width": 757, "top": 764, "height": 36, "left": 268}, "words": "者经筛查为EGFR阳性,适合应用西妥昔单抗进行泊疗:尚无本品对EGFR阴性肿瘤患者"}, {"probability": {"variance": 0.00776, "average": 0.970376, "min": 0.575625}, "location": {"width": 761, "top": 791, "height": 38, "left": 271}, "words": "的有效性及安全性数据。在欧洲和美国已进行了两项西妥昔单抗与伊立替康联合用药的"}, {"probability": {"variance": 0.013981, "average": 0.959295, "min": 0.350053}, "location": {"width": 762, "top": 821, "height": 37, "left": 267}, "words": "临床试验。共有365个近期经含伊立替康细胞毒治疗方案治疗失败的EGR阳性的转移"}, {"probability": {"variance": 0.014424, "average": 0.967031, "min": 0.442851}, "location": {"width": 766, "top": 850, "height": 37, "left": 265}, "words": "性结直肠癌患者入选,其KPS不低于60。但在接受联合治疗后,大部分者的KPS都大"}, {"probability": {"variance": 4e-06, "average": 0.998007, "min": 0.994038}, "location": {"width": 85, "top": 880, "height": 24, "left": 266}, "words": "于等于80"}, {"probability": {"variance": 0.002452, "average": 0.980049, "min": 0.722111}, "location": {"width": 716, "top": 905, "height": 36, "left": 312}, "words": "MR62202-007:本项随机试验是比较西妥昔单抗加伊立替康联合治疗(218例有"}, {"probability": {"variance": 0.009518, "average": 0.967589, "min": 0.473517}, "location": {"width": 764, "top": 935, "height": 32, "left": 262}, "words": "效病例)和西妥昔单抗单药治疗(11例有效病例)的有效性和安全性。在联合治疗组"}, {"probability": {"variance": 0.001148, "average": 0.992106, "min": 0.776846}, "location": {"width": 763, "top": 961, "height": 39, "left": 262}, "words": "中,伊立替康的用药方案为:125mg/m2体表面积,连续4周每周给药一次,随后停药两"}, {"probability": {"variance": 0.00957, "average": 0.968621, "min": 0.425123}, "location": {"width": 763, "top": 992, "height": 35, "left": 261}, "words": "周或每两周的给药剂量为180mg/m2体表面积;或每三周的给药剂量为350mg/m2体表面"}, {"probability": {"variance": 0.001226, "average": 0.989034, "min": 0.801478}, "location": {"width": 760, "top": 1023, "height": 30, "left": 262}, "words": "积;或参照伊立替康的使用说明书推荐的剂量进行调整。其中半数以上的患者采用的给"}, {"probability": {"variance": 0.007714, "average": 0.974964, "min": 0.443774}, "location": {"width": 761, "top": 1050, "height": 31, "left": 262}, "words": "药剂量为每两周180mg/m2体表面积。西妥昔单抗单药治疗组的患者如发生疾病进展,则"}, {"probability": {"variance": 0.001287, "average": 0.985248, "min": 0.840848}, "location": {"width": 762, "top": 1075, "height": 36, "left": 260}, "words": "继续采用西妥昔单抗加用伊立替康(伊立替康的给药剂量与进入本试验之前患者的使用"}, {"probability": {"variance": 8e-06, "average": 0.997661, "min": 0.990134}, "location": {"width": 279, "top": 1104, "height": 28, "left": 263}, "words": "剂量相同)的方案进行联合治疗"}, {"probability": {"variance": 0.006855, "average": 0.975605, "min": 0.505058}, "location": {"width": 687, "top": 1132, "height": 35, "left": 318}, "words": "CLCP02-9923:本试验为单组开放试验,共入选138例有效病例接受联合治疗"}, {"probability": {"variance": 0.000393, "average": 0.988756, "min": 0.910056}, "location": {"width": 749, "top": 1159, "height": 38, "left": 259}, "words": "其中约90%的患者的伊立替康用药方案为125mg/m2体表面积,连续4周每周给药一次"}, {"probability": {"variance": 0, "average": 0.999529, "min": 0.998814}, "location": {"width": 124, "top": 1192, "height": 25, "left": 258}, "words": "随后停药两周"}, {"probability": {"variance": 0.002198, "average": 0.976304, "min": 0.831849}, "location": {"width": 498, "top": 1223, "height": 31, "left": 256}, "words": "以上两项试验中,西妥昔单抗的给药剂量见“用法用量”"}, {"probability": {"variance": 0, "average": 0.999064, "min": 0.997945}, "location": {"width": 323, "top": 1254, "height": 26, "left": 255}, "words": "以上试验中的有效性数据如下表所述"}, {"probability": {"variance": 0.005891, "average": 0.945693, "min": 0.788186}, "location": {"width": 45, "top": 1377, "height": 17, "left": 268}, "words": "22-077"}, {"probability": {"variance": 0.039001, "average": 0.858683, "min": 0.447089}, "location": {"width": 137, "top": 1376, "height": 19, "left": 412}, "words": "2850(22.9)17."}, {"probability": {"variance": 0.013606, "average": 0.96659, "min": 0.431351}, "location": {"width": 719, "top": 1512, "height": 37, "left": 291}, "words": "西妥单抗与伊立替康联合治疗组的客观有效率(OR)、疾病控制率(DCR)和无"}, {"probability": {"variance": 0.004035, "average": 0.975431, "min": 0.658556}, "location": {"width": 757, "top": 1541, "height": 36, "left": 250}, "words": "进展生存期(PFS)均优于西妥昔单抗单药治疗组。在EMR62202-007试验中没有观察"}, {"probability": {"variance": 3.8e-05, "average": 0.995881, "min": 0.974589}, "location": {"width": 526, "top": 1572, "height": 29, "left": 249}, "words": "到两组之间总生存期的统计学差异(风险比0.91,p=0.48)"}, {"probability": {"variance": 0.000147, "average": 0.996429, "min": 0.926716}, "location": {"width": 719, "top": 1599, "height": 37, "left": 288}, "words": "目前尚缺乏本品在中国人进行的临床研究资料,但一项在亚太地区完成的西妥昔单"}, {"probability": {"variance": 0.00014, "average": 0.995576, "min": 0.931176}, "location": {"width": 751, "top": 1630, "height": 37, "left": 247}, "words": "抗与卡铂联合治疗含铂方案化疗失败的复发或转移性鼻咽癌研究中(EMR62202-003)"}, {"probability": {"variance": 7e-06, "average": 0.998201, "min": 0.987639}, "location": {"width": 696, "top": 1659, "height": 35, "left": 246}, "words": "本品显示出良好的安全性和有效性(疾病控制率为60%;中位生存期为8个月)"}], "language": -1}